RE:RE:The Buyout Window True but...
Buyout offers typically come with a due diligence period , including a period of time where both parties shareholders can absorb, vote on, and otherwise ratify the deal.
Not saying it'll happen for sure, but nothing ( that I can see) precludes an offer being made prior to Top Line data release that is voted upon by both sides following said release, allowing for full consideration of all available data at the time, including Top Line data.
Deals can also come with an escape clause should for example the Top Line data not meet an acceptable threshold. What is interesting to consider is what to do with the very low potential of a subsequent event such as ultimate rejection by the FDA in subsequent months, for whatever reason despite good to great Top Line data ?
Investors are reminded that two shareholders combined own over 40% of the shares and presumably would not have too much trouble securing the necessary votes should "the right offer" come along. Of course majority shareholders, the BOD and management must be seen as acting fairly and in the best interest of all shareholders, in terms of maximizing shareholder value.
All speculation of course...nothing is guaranteed.
MM